Meyer C - Search Results

1

Comparative Assessment of Protein Kinase Inhibitors in Public Databases and in PKIDB.

Bournez C, Carles F, Peyrat G, Aci-Sèche S, Bourg S, Meyer C, Bonnet P. Bournez C, et al. Among authors: meyer c. Molecules. 2020 Jul 15;25(14):3226. doi: 10.3390/molecules25143226. Molecules. 2020. PMID: 32679723 Free PMC article.

2

The use of novel selectivity metrics in kinase research.

Bosc N, Meyer C, Bonnet P. Bosc N, et al. Among authors: meyer c. BMC Bioinformatics. 2017 Jan 5;18(1):17. doi: 10.1186/s12859-016-1413-y. BMC Bioinformatics. 2017. PMID: 28056771 Free PMC article.

3

PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials.

Carles F, Bourg S, Meyer C, Bonnet P. Carles F, et al. Among authors: meyer c. Molecules. 2018 Apr 15;23(4):908. doi: 10.3390/molecules23040908. Molecules. 2018. PMID: 29662024 Free PMC article.

4

A Proteometric Analysis of Human Kinome: Insight into Discriminant Conformation-dependent Residues.

Bosc N, Wroblowski B, Aci-Sèche S, Meyer C, Bonnet P. Bosc N, et al. Among authors: meyer c. ACS Chem Biol. 2015 Dec 18;10(12):2827-40. doi: 10.1021/acschembio.5b00555. Epub 2015 Oct 16. ACS Chem Biol. 2015. PMID: 26411811

5

Prediction of Protein Kinase-Ligand Interactions through 2.5D Kinochemometrics.

Bosc N, Wroblowski B, Meyer C, Bonnet P. Bosc N, et al. Among authors: meyer c. J Chem Inf Model. 2017 Jan 23;57(1):93-101. doi: 10.1021/acs.jcim.6b00520. Epub 2017 Jan 3. J Chem Inf Model. 2017. PMID: 27983837

6

Conformational analysis of r207910, a new drug candidate for the treatment of tuberculosis, by a combined NMR and molecular modeling approach.

Gaurrand S, Desjardins S, Meyer C, Bonnet P, Argoullon JM, Oulyadi H, Guillemont J. Gaurrand S, et al. Among authors: meyer c. Chem Biol Drug Des. 2006 Aug;68(2):77-84. doi: 10.1111/j.1747-0285.2006.00410.x. Chem Biol Drug Des. 2006. PMID: 16999772

7

Protocols for the Design of Kinase-focused Compound Libraries.

Jacoby E, Wroblowski B, Buyck C, Neefs JM, Meyer C, Cummings MD, van Vlijmen H. Jacoby E, et al. Among authors: meyer c. Mol Inform. 2018 May;37(5):e1700119. doi: 10.1002/minf.201700119. Epub 2017 Nov 8. Mol Inform. 2018. PMID: 29116686

8

Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy.

Lu T, Schubert C, Cummings MD, Bignan G, Connolly PJ, Smans K, Ludovici D, Parker MH, Meyer C, Rocaboy C, Alexander R, Grasberger B, De Breucker S, Esser N, Fraiponts E, Gilissen R, Janssens B, Peeters D, Van Nuffel L, Vermeulen P, Bischoff J, Meerpoel L. Lu T, et al. Among authors: meyer c. Bioorg Med Chem Lett. 2018 Jul 1;28(12):2159-2164. doi: 10.1016/j.bmcl.2018.05.014. Epub 2018 May 8. Bioorg Med Chem Lett. 2018. PMID: 29779975

9

Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207.

Guillemont J, Meyer C, Poncelet A, Bourdrez X, Andries K. Guillemont J, et al. Among authors: meyer c. Future Med Chem. 2011 Sep;3(11):1345-60. doi: 10.4155/fmc.11.79. Future Med Chem. 2011. PMID: 21879841

10

4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.

Benjahad A, Croisy M, Monneret C, Bisagni E, Mabire D, Coupa S, Poncelet A, Csoka I, Guillemont J, Meyer C, Andries K, Pauwels R, de Béthune MP, Himmel DM, Das K, Arnold E, Nguyen CH, Grierson DS. Benjahad A, et al. Among authors: meyer c. J Med Chem. 2005 Mar 24;48(6):1948-64. doi: 10.1021/jm0408621. J Med Chem. 2005. PMID: 15771439

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,360 results

Search Page